Clinical trials: Liver Transplant Failure
End Stage Liver Disease, Hepatic Encephalopathy
Prediction of Mortality in Patients Waiting for Liver Transplantation Through Brain Magnetic Resonance Imaging
The purpose of this study is to determine whether hepatic encephalopathy, measured through magnetic resonance imaging, electroencephalogram and neuropsychological evaluation adds prognostic information to patients who are waiting…
- Trial name
- NCT01434056
- Where
- Brazil
- Volunteers
- 400 people
- Sponsor
- Hospital Israelita Albert Einstein
Liver Transplantation
Hemodynamic Measurements During Liver Transplantation
The purpose of the study is to determine if the less invasive monitors are as reliable for measuring heart function in patients undergoing liver transplantation as the more invasive pulmonary artery.
- Trial name
- OLT (NCT00682110)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
Liver Transplant; Complications, COVID19
COVID-19 in Liver Transplant Recipients
Prospective observational study aimed at analyzing the incidence, clinical characteristics and outcomes of COVID-19 in LT in Spain.
- Conditions
- Liver Transplant; Complications, COVID19, Respiratory Failure
- Trial name
- COVID19-SETH (NCT04361591)
- Testing
- Observational only
- Where
- Spain
- Volunteers
- 121 people
- Sponsor
- Hospital Clinic of Barcelona
Hepatic Failure
Pyrophosphate Homeostasis and Hepatic Expression of ABCC6.Pyro-TH
In animals, normal hepatic expression of ABCC6 (ATP-binding transporter cassette, subfamily C, member 6) determines plasma pyrophosphate (PPi) concentration.
- Trial name
- Pyro-TH (NCT03576859)
- Testing
- blood sample
- Where
- France
- Volunteers
- 38 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Liver Transplantation
Prospective Evaluation of Predictors for Organ Failure Following Liver Transplantation
Early organ failure occurs frequently and is difficult to predict. The study aims to define a predictive score for early transplant failure.
- Trial name
- NCT00408889
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Heidelberg University
Terminal Liver Disease, Ischemia Reperfusion Injury
TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion
Utilisation of extended criteria donors due to critical organ shortage contributes to increased ischemia reperfusion injury as well as mortality following liver transplantation.
- Conditions
- Terminal Liver Disease, Ischemia Reperfusion Injury, Graft Dysfunction, Graft Failure
- Trial name
- TOP (NCT01564095)
- Testing
- Tacrolimus
- Where
- 7 sites in Germany
- Volunteers
- 25 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Hepatocellular Carcinoma Non-resectable
Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma
Currently in France, hepatocellular carcinoma (HCC) represents over 30% of indications of liver transplantation (LT) (# 500 cases/year).
- Trial name
- Ta-Len-Tra (NCT05901194)
- Testing
- Lenvatinib
- Where
- 6 sites in France
- Volunteers
- 25 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Biliary Atresia, Metabolic Disorders
Clinical and Basic Study for Pediatric Liver Transplantation
Background: In mainland China, the development of pediatric liver transplantation (LT) has lagged behind that of adult LT during the past two decades, but it has been progressing immensely in recent years.
- Conditions
- Biliary Atresia, Metabolic Disorders, Fulminant Liver Failure, Hepatic Tumors
- Trial name
- CBSPLT (NCT02503384)
- Where
- China
- Volunteers
- 180 people
- Sponsor
- RenJi Hospital
Liver Transplant Failure
Analysis of Donor-derived Cell Free DNA in Liver Transplant Patients
Determine the levels of Donor-derived (dd)cell-free DNA(cfDNA )in liver transplant recipients with normal liver function tests (LFTs) indicating stable immunosuppression status (IS).
- Trial name
- NCT06225206
- Testing
- donor-derived cell free DNA in liver
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Methodist Health System
Septic Shock, Acute Respiratory Distress Syndrome
CytOSorb TreatMent Of Critically Ill PatientS Registry
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based…
- Conditions
- Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
- Trial name
- COSMOS (NCT05146336)
- Testing
- CytoSorb
- Where
- 28 sites in Austria, Germany and 4 more
- Volunteers
- 3,000 people
- Sponsor
- CytoSorbents, Inc
Liver Transplantation (LT), End-stage Liver Disease (ESLD)
Restrictive Fluid Management In Liver Transplantation (REFIL)
The goal of the REFIL-2 study is to evaluate the effectiveness of a low splanchnic blood volume restrictive fluid management strategy (a strategy that involves limiting fluid administration and prioritizing the use of medications…
- Trial name
- REFIL-2 (NCT07695363)
- Testing
- Low splanchnic blood volume restrictive fluid management strategy, Phlebotomy, Optimized cardiac output liberal fluid management strategy
- Where
- 4 sites in Canada
- Volunteers
- 866 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Kidney Failure
Everolimus Monotherapy as Immunosuppression After Liver Transplant
Tacrolimus is the standard immunosuppressive drug used to prevent organ rejection post liver transplant. One side effect of Tacrolimus is nephrotoxicity. Everolimus does not have the nephrotoxicity side effects of Tacrolimus.
- Trial name
- NCT04063865
- Testing
- Tacrolimus, Everolimus
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Indiana University
Hepatitis C, Hepatitis C, Chronic
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
In order to prevent organ rejection, patients receiving liver transplants currently require life-long treatment with immune system-suppressing medications to prevent the rejection of the transplanted liver.
- Conditions
- Hepatitis C, Hepatitis C, Chronic, Nonimmune Nonviral Causes of Liver Failure
- Trial name
- A-WISH (NCT00135694)
- Testing
- calcineurin inhibitor-based immunosuppression, liver transplant, corticosteroids
- Where
- 8 sites in United States
- Volunteers
- 275 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)